Eligard
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Eligard (leuprolide; Astellas/Tolmar Pharmaceuticals) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.” Persistent use of GnRH agonists over time causes downregulation of GnRH receptors in the pituitary gland, generating a significant reduction in LH and follicle-stimulating hormone secretion. This has the effect of complete shutdown of testosterone production in the testes, resulting in chemical castration.
TABLE OF CONTENTS
4 Product Profiles
4 Eligard : Prostate cancer
LIST OF FIGURES
5 Figure 1: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Firmagon 
Sign up to the